Dalton Greiner Hartman Maher & Co. purchased a new position in Innophos Holdings, Inc. (NASDAQ:IPHS) during the second quarter, according to its most recent filing with the SEC. The institutional investor purchased 39,726 shares of the specialty chemicals company’s stock, valued at approximately $1,742,000. Dalton Greiner Hartman Maher & Co. owned about 0.21% of Innophos Holdings as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Private Advisor Group LLC acquired a new stake in Innophos Holdings during the first quarter worth $200,000. Barings LLC acquired a new stake in Innophos Holdings during the first quarter worth $200,000. State of Alaska Department of Revenue raised its stake in Innophos Holdings by 81.4% in the first quarter. State of Alaska Department of Revenue now owns 3,810 shares of the specialty chemicals company’s stock worth $205,000 after buying an additional 1,710 shares during the period. Curbstone Financial Management Corp acquired a new stake in Innophos Holdings during the first quarter worth $208,000. Finally, GHP Investment Advisors Inc. acquired a new stake in Innophos Holdings during the first quarter worth $223,000. Hedge funds and other institutional investors own 94.32% of the company’s stock.
Shares of Innophos Holdings, Inc. (NASDAQ:IPHS) traded up 14.80% during trading on Tuesday, reaching $47.95. 188,525 shares of the company traded hands. The company has a market capitalization of $929.08 million, a price-to-earnings ratio of 20.58 and a beta of 0.86. Innophos Holdings, Inc. has a 1-year low of $37.02 and a 1-year high of $58.22. The stock’s 50 day moving average is $43.46 and its 200 day moving average is $47.22.
Innophos Holdings (NASDAQ:IPHS) last released its earnings results on Tuesday, August 1st. The specialty chemicals company reported $0.57 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.04. Innophos Holdings had a return on equity of 14.11% and a net margin of 6.56%. The business had revenue of $179.14 million for the quarter, compared to analyst estimates of $172.65 million. During the same quarter in the previous year, the company posted $0.63 earnings per share. The company’s revenue for the quarter was down 1.5% compared to the same quarter last year. On average, analysts forecast that Innophos Holdings, Inc. will post $2.49 EPS for the current year.
IPHS has been the subject of several analyst reports. Sidoti raised shares of Innophos Holdings from a “neutral” rating to a “buy” rating in a research report on Friday, May 26th. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Innophos Holdings from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. Finally, BidaskClub downgraded shares of Innophos Holdings from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th.
Innophos Holdings Company Profile
Innophos Holdings, Inc is a producer of nutritional specialty ingredients with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets. The Company also provides bioactive mineral and nutritional ingredients. The Company’s segments include Specialty Phosphates US & Canada, Specialty Phosphates Mexico, and Granular Triple Super Phosphate (GTSP) & Other.
Receive News & Ratings for Innophos Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
